EU/3/05/261
About
On 7 March 2005, orphan designation (EU/3/05/261) was granted by the European Commission to Bausch & Lomb (UK) Ltd, United Kingdom, for fluocinolone acetonide (prolonged-release intravitreal implant) for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
The sponsorship was transferred to Bausch & Lomb Ireland in October 2006.
Key facts
Active substance |
Fluocinolone acetonide
|
Disease / condition |
Treatment of non-infectious uveitis affecting the posterior segment of the eye
|
Date of first decision |
07/03/2005
|
Outcome |
Positive
|
EU designation number |
EU/3/05/261
|
Sponsor's contact details
Bausch & Lomb Ireland
IDA Industrial Park
Waterford
Ireland
Telephone: + 353 51 35 501
Telefax: + 353 51 35 56 39
E-mail: waterfordinfo@bausch.com
IDA Industrial Park
Waterford
Ireland
Telephone: + 353 51 35 501
Telefax: + 353 51 35 56 39
E-mail: waterfordinfo@bausch.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: